April 24, 2024

Taylor Daily Press

Complete News World

Recommendations for less common non-tuberculous mycobacterial lung diseases

Recommendations for less common non-tuberculous mycobacterial lung diseases

A panel of experts participates in Lancet Infectious Diseases Recommendations for the treatment of lung disease caused by less common non-tuberculous mycobacteria not discussed in the 2020 ATS/ERS/ESCMID/IDSA Guidelines.

2020 Guidelines for the Treatment of Non-Tuberculous Fungal Lung Disease (NTM-PD) from the American Thoracic Society, European Respiratory Society, European Society of Clinical Microbiology and Infectious Diseases, and American Infectious Diseases Society; The British Thoracic Society Guidelines 2017 treat lung disease in adults caused by Mycobacterium avialis-compound, Mycobacterium kansaAnd the Mycobacterium xenopia And the Mycobacterium abscess. To make evidence-based recommendations for the treatment of less common types of Mycobacterium non-tuberculosis (NTM) in adult patients without cystic fibrosis or HIV infection, an expert panel made up of members of the ATS/ERS/ESCMID/IDSA Steering Committee since 2020 has conducted a A systematic literature search to establish guidelines for lung diseases caused by 7 additional organisms: Mycobacterium chelonaeAnd the Mycobacterium osseousAnd the Mycobacterium genavenseAnd the Mycobacterium gordonaeAnd the Mycobacterium malmonsAnd the Mycobacterium simia And the Mycobacterium szulgai.

Treatment recommendations were developed through a structured consensus process. Evidence from the scientific literature published in English for the treatment of lung disease caused by 6 of these types of non-defining measures was very low quality, with the exception of M. malmoenseIt was based on evaluation of case reports and case series. Before M. malmoense The results of 2 randomized controlled trials and 3 retrospective cohort studies provided a better evidence base for treatment recommendations, although the evidence remains of low quality.

source:
Lange C, Böttger EC, Cambau E, et al. Consensus management recommendations for less common non-tuberculous fungal lung diseases. Lancet infects dis. 2022; 22: e178-90.

See also  Work to be done: Recalibrate the bottom line policy